Oncotelic Therapeutics, Inc. (OTCQB: OTLC) released its first-quarter 2026 financial results and a corporate update on Tuesday, highlighting continued advancement across its oncology, AI-enabled drug development and advanced drug delivery initiatives. The company reported progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform, while maintaining the previously established fair value of its 45% ownership interest in GMP Biotechnology at approximately $388 million as of March 31, 2026.
The clinical-stage biopharmaceutical company is focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. This platform is a key differentiator, enabling the company to streamline drug development and identify potential therapeutic candidates more efficiently.
In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% stake in GMP Bio, which advances a complementary pipeline of therapeutic candidates in oncology and rare diseases.
The company’s capital-efficient growth strategy is evident as it continues to pursue diversified biotechnology initiatives without significant dilution. The maintenance of the GMP Biotechnology valuation underscores the perceived value of this joint venture, which strengthens Oncotelic’s position in the oncology and rare disease therapeutics market.
For more details on the full press release, visit https://ibn.fm/DTVsF. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Reports Q1 2026 Results, Advances AI-Driven Drug Development and CNS Delivery Platform.